The french business magazine Newzy published in its November issue an article about IMSTAR’s latest developments concerning tailored tools in cancer diagnostic and treatment and human genomic risk assessment.

IMSTAR’s innovative solution for multiplex phenotyping by high throughput functional cellular analysis is examplified by its pilote position in BIOTYPE research program co-funded by the French Ministry of Industry and the Paris region. In addition, the company is a key actor for human genomic risk assessment thanks to its leadership in automated scoring of genetic toxicology assays.